This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

SYNLAB Valuation

Q: What is the Fair Price of SYAB when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

SYAB (€11.06) is trading above our estimate of [[fair value]] (€6.22)

Is SYAB undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of SYAB when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: SYAB (€11.06) is trading above our estimate of fair value (€6.22)

Significantly Below Fair Value: SYAB is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for SYAB?

Key metric: As SYAB is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for SYAB. This is calculated by dividing SYAB's market cap by their current earnings.
What is SYAB's PE Ratio?
PE Ratio	27.2x
Earnings	€89.35m
Market Cap	€2.43b

SYAB key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	1.4x
Enterprise Value/EBITDA	12.6x
PEG Ratio	-2.4x

Price to Earnings Ratio vs Peers

How does SYAB's PE Ratio compare to its peers?

The above table shows the PE ratio for SYAB vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	20.6x
FME Fresenius Medical Care	18.8x	19.3%	€12.4b
FRE Fresenius SE KGaA	n/a	39.0%	€18.8b
RHK RHÖN-KLINIKUM	18.6x	7.5%	€836.7m
AFX Carl Zeiss Meditec	24.4x	16.3%	€5.0b
SYAB SYNLAB	27.2x	-11.4%	€2.4b

Price-To-Earnings vs Peers: SYAB is expensive based on its Price-To-Earnings Ratio (27.2x) compared to the peer average (23x).

Price to Earnings Ratio vs Industry

How does SYAB's PE Ratio compare vs other companies in the European Healthcare Industry?

2 Companies	Price / Earnings	Estimated Growth	Market Cap

2 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: SYAB is expensive based on its Price-To-Earnings Ratio (27.2x) compared to the European Healthcare industry average (18.8x).

Price to Earnings Ratio vs Fair Ratio

What is SYAB's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SYAB PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	27.2x
Fair PE Ratio	14.6x

Price-To-Earnings vs Fair Ratio: SYAB is expensive based on its Price-To-Earnings Ratio (27.2x) compared to the estimated Fair Price-To-Earnings Ratio (14.6x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

LNA Santé

€244.4m

Engages in the management and operation of health establishments.

2N3

€23.25

-6.1%

16.0%

Shandong Weigao Group Medical Polymer

HK$20.1b

Engages in the research and development, production, wholesale, and sale of medical devices in the People’s Republic of China.

UK2

HK$0.52

-1.0%

-38.8%

Top Glove Corporation Bhd

RM 7.8b

An investment holding company, manufactures, trades in, and sells gloves in Malaysia, Thailand, the People’s Republic of China, and internationally.

5OU

RM 0.98

0.5%

-82.5%